Publikationen
Folgende Arbeiten wurden bisher publiziert:
Artikel, Reviews und Case Reports:
Benoit TM, Schwotzer R, Schneiter D, et al. Rare cause of emphysema. Thorax 2021;76:421-422.
Brouwers S, Heimgartner R, Laptseva N, Aguzzi A, Ehl NF, Fehr T, Hitz F, Jung HH, Kälin J, Manz MG, Müllhaupt B, Ruschitzka F, Seeger H, Stussi G, Zweier M, Flammer AJ, Gerber B, Schwotzer R. Historic characteristics and mortality of patients in the Swiss Amyloidosis Registry. Swiss Med Wkly [Internet]. 2024 Feb. 15 [cited 2024 Apr. 4];154(2):3485. Available from: https://smw.ch/index.php/smw/article/view/3485
Brouwers S, Laptseva N, Gerber B, Schwotzer R, Ruschitzka F, Flammer AJ. Cardiac amyloidosis. Cardiovasc Med. 2018;21(11):00592 Open access closed->pdf?
Chen Z, Shi A, Dong H, Laptseva N, Chen F, Yang J, Guo X, Duru F, Chen K, Chen L. Prognostic implications of premature ventricular contractions and non-sustained ventricular tachycardia in light-chain cardiac amyloidosis. Europace. 2024 Mar 1;26(3):euae063. doi: 10.1093/europace/euae063. PMID: 38466042; PMCID: PMC10969534.
Marchi, Francesco, Chiara Kessler, Daniela Distefano, Lodovico Terzi di Bergamo, Luca Fumagalli, Manuela Averaimo, Emanuele Crupi, et al. “Prevalence of Amyloid in Ligamentum Flavum of Patients with Lumbar Spinal Stenosis.” Amyloid 30, no. 4 (2023): 416–23. doi:10.1080/13506129.2023.2230516.
Nadia Djerbi, Friederike Vetter, Rahel Schwotzer. Neues zur Diagnostik und Therapie der AL-Amyloidose. SCHWEIZER ZEITSCHRIFT FÜR ONKOLOGIE 2/2022
Gastl M, Peereboom SM, Gotschy A, Fuetterer M, von Deuster C, Boenner F, Kelm M, Schwotzer R, Flammer AJ, Manka R, Kozerke S. Myocardial triglycerides in cardiac amyloidosis assessed by proton magnetic resonance spectroscopy. J Cardiovasc Magn Reson 2019 Jan 31;21(1):10
Ghilardi, G., Stussi, G., Mazzucchelli, L., Röcken, C., Rossi, D., & Gerber, B. (2019). Venetoclax plus daratumumab induce hematological CR and organ response in an AL amyloidosis patient with t(11;14). Amyloid, 26(3), 173–174. https://doi.org/10.1080/13506129.2019.1615428
Gotschy A, von Deuster C, van Gorkum RJH, Gastl M, Vintschger E, Schwotzer R, Flammer AJ, Manka R, Stoeck CT, Kozerke S. Characterizing cardiac involvement in amyloidosis using in-vivo cardiac diffusion tensor imaging. J Cardiovasc Magn Reson 2019 Sep 5;21(1):56
Huss-Mischler K, Kurzen J-L, Rüschoff JH, Schwotzer R. Rätselhafte bipulmonale Konsolidationen und Noduli. Swiss Medical Forum 2024;24(13–14):180–183
Laptseva N, Brouwers S, Schwotzer R, Flammer AJ. Kardiale Amyloidose als Ursache einer Herzinsuffizienz. Cardiovasc : Interdisziplinäre Fortbildung, 18(2):6-10.
Laptseva, Natallia & Rossi, Valentina & Sudano, Isabella & Schwotzer, Rahel & Ruschitzka, Frank & Flammer, Andreas & Duru, Firat. (2023). Arrhythmic Manifestations of Cardiac Amyloidosis: Challenges in Risk Stratification and Clinical Management. Journal of Clinical Medicine. 12. 2581. 10.3390/jcm12072581.
Laptseva N, Zuber M, Bode PK, Flammer AJ. Cardiac amyloidosis: still challenging. Eur Heart J. 2017 Jan 7;38(2):122. doi: 10.1093/eurheartj/ehw290. PMID: 27406183.
Rüfer A, Schwotzer R. Systemic AL Amyloidosis and Precision Medicine. healthbook TIMES Onco Hema 2021; (8): 32–41
Schwotzer R, Manz MG, Pederiva S, et al. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden. Hematological Oncology. 2019; 37: 595–600
Schwotzer R, Gerber B. „Die Leichtketten(AL)-Amyloidose ist nicht einfach ein Myelom“. Leading Opinions Hämatologie&Onkologie 6/15:148-152
Schwotzer R, Gerber B, Flammer AJ. «Therapie der AL-Amyloidose». Leading Opinions Hämatologie&Onkologie 3/18:23-27
Voglis S, Yildiz Y, von Faber-Castell F, Harnisch KJ, Regli L, Bellut D, Schwotzer R, Germans MR. Surgically treated intradural spinal manifestation of hereditary amyloidogenic transthyretin amyloidosis - A case report and scoping review of the literature. Brain and Spine 2 (2022) 100876
Zampiccoli E, Barthelmes J, Kreysing L, Nägele MP, Nebunu D, Haider T, von Eckardstein A, Gerber B, Schwotzer R, Ruschitzka F, Sudano I, Flammer AJ. Eyes on amyloidosis: microvascular retinal dysfunctionin cardiac amyloidosis. ESC Heart Failure (2022)
Guidelines SAN:
Condoluci A, Théaudin M, Schwotzer R, Pazhenkottil AP, Arosio P, Averaimo M, Bacher U, Bode P, Cavalli A, Dirnhofer S, Djerbi N, Dobner S, Fehr T, Garofalo M, Gaspert A, Gerull S, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Magini G, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pabst T, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Treglia G, Tzankov A, Vetter F, Zweier M, Flammer AJ, Gerber B. Management of transthyretin amyloidosis. Guidelines from the 1st Swiss Amyloidosis Network (SAN) Consensus conference. Swiss Med Wkly. 2021 Oct 20;151:w30053. doi: 10.4414/smw.2021.w30053. Erratum in: Swiss Med Wkly. 2021 Nov 04;151:w30104. PMID: 34694105.
Schwotzer R, Flammer AJ, Gerull S, Pabst T, Arosio P, Averaimo M, Bacher U, Bode P, Cavalli A, Condoluci A, Dirnhofer S, Djerbi N, Dobner SW, Fehr T, Garofalo M, Gaspert A, Heimgartner R, Hübers A, Jung HH, Kessler C, Knöpfel R, Laptseva N, Manka R, Mazzucchelli L, Meyer M, Mihaylova V, Monney P, Mylonas A, Nkoulou R, Pazhenkottil AP, Pfister O, Rüfer A, Schmidt A, Seeger H, Stämpfli SF, Stirnimann G, Suter T, Théaudin M, Treglia G, Tzankov A, Vetter F, Zweier M, Gerber B. Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly [Internet]. 2020 Dec. 5 [cited 2024 Apr. 4];150(4950):w20364. Available from: https://smw.ch/index.php/smw/article/view/2912